1066 related articles for article (PubMed ID: 25751757)
1. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.
Ewertz M; Qvortrup C; Eckhoff L
Acta Oncol; 2015 May; 54(5):587-91. PubMed ID: 25751757
[TBL] [Abstract][Full Text] [Related]
2. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Hershman DL; Lacchetti C; Dworkin RH; Lavoie Smith EM; Bleeker J; Cavaletti G; Chauhan C; Gavin P; Lavino A; Lustberg MB; Paice J; Schneider B; Smith ML; Smith T; Terstriep S; Wagner-Johnston N; Bak K; Loprinzi CL;
J Clin Oncol; 2014 Jun; 32(18):1941-67. PubMed ID: 24733808
[TBL] [Abstract][Full Text] [Related]
3. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
5. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced neuropathy: A comprehensive survey.
Miltenburg NC; Boogerd W
Cancer Treat Rev; 2014 Aug; 40(7):872-82. PubMed ID: 24830939
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
[TBL] [Abstract][Full Text] [Related]
8. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy.
Aziz MT; Good BL; Lowe DK
Ann Pharmacother; 2014 May; 48(5):626-32. PubMed ID: 24577146
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics.
Hopkins HL; Duggett NA; Flatters SJL
Curr Opin Support Palliat Care; 2016 Jun; 10(2):119-128. PubMed ID: 27054288
[TBL] [Abstract][Full Text] [Related]
10. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
[TBL] [Abstract][Full Text] [Related]
11. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
12. Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.
Chu SH; Lee YJ; Lee ES; Geng Y; Wang XS; Cleeland CS
Support Care Cancer; 2015 Feb; 23(2):513-24. PubMed ID: 25256375
[TBL] [Abstract][Full Text] [Related]
13. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy-induced peripheral neuropathy].
Noguchi E; Maeda Y
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1773-6. PubMed ID: 22083183
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice.
Wickham R
Clin J Oncol Nurs; 2007 Jun; 11(3):361-76. PubMed ID: 17623621
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced peripheral neuropathy: prevention and treatment.
Pachman DR; Barton DL; Watson JC; Loprinzi CL
Clin Pharmacol Ther; 2011 Sep; 90(3):377-87. PubMed ID: 21814197
[TBL] [Abstract][Full Text] [Related]
17. [Peripheral neuropathy as a side effect of chemotherapy and targeted therapy].
Gießen-Jung C; von Baumgarten L
Dtsch Med Wochenschr; 2018 Jul; 113(13):970-978. PubMed ID: 29972842
[TBL] [Abstract][Full Text] [Related]
18. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.
Smith EM; Pang H; Ye C; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Le-Lindqwister N; Fadul CE; Loprinzi C; Shapiro CL;
Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26603828
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced peripheral neuropathy and rehabilitation: A review.
Zhang S
Semin Oncol; 2021 Jun; 48(3):193-207. PubMed ID: 34607709
[TBL] [Abstract][Full Text] [Related]
20. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.
Gewandter JS; Mohile SG; Heckler CE; Ryan JL; Kirshner JJ; Flynn PJ; Hopkins JO; Morrow GR
Support Care Cancer; 2014 Jul; 22(7):1807-14. PubMed ID: 24531792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
